Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.24 Analyst target: $7.50 Upside: 234.82%
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company is headquartered in Austin, Texas.
See the full interactive analysis & chart →Informational only — not investment advice.